Evolva Holding Competitors
| EVE Stock | CHF 0.84 0.01 1.20% |
Pair Correlation for Evolva Holding and Santhera Pharmaceuticals View
Very poor diversification
For the present investment horizon, the measured correlation between EVE and SANN stands at 0.8, or Very poor diversification. This matters because lower overlap can improve diversification, while higher overlap leaves more of the same risk inside the portfolio.
Moving together with Evolva Stock
Mean reversion in Evolva Holding's price occurs when temporary dislocations - caused by sentiment extremes, news events, or liquidity shocks - correct back toward the stock's historical fair value.
Evolva Holding Competition Correlation Matrix
Reviewing how Evolva Holding SA moves relative to competing stocks can show whether peer exposure is reducing portfolio risk or simply repeating the same market bet. A reading near +1 usually means prices have moved in tandem, a reading near -1 suggests opposite movement, and a reading near zero points to weaker historical dependence.
| 0.32 | -0.59 | 0.73 | -0.67 | ADXN | ||
| 0.32 | -0.07 | 0.3 | -0.02 | BSLN | ||
| -0.59 | -0.07 | -0.46 | 0.7 | MOLN | ||
| 0.73 | 0.3 | -0.46 | -0.44 | NWRN | ||
| -0.67 | -0.02 | 0.7 | -0.44 | SANN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Evolva Holding Company may look attractive on headline returns alone, but deeper analysis often tells a different story. A thorough review of Evolva Holding's risk-adjusted indicators provides a clearer picture of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ADXN | 2.76 | -0.34 | 0.00 | -0.37 | 0.00 | 6.00 | 18.70 | |||
| BSLN | 1.62 | 0.06 | 0.00 | -0.02 | 0.00 | 3.01 | 10.08 | |||
| MOLN | 2.68 | 0.13 | 0.09 | -0.19 | 3.25 | 6.55 | 19.98 | |||
| NWRN | 2.77 | -0.23 | 0.00 | -0.27 | 0.00 | 6.60 | 16.79 | |||
| SANN | 2.71 | 0.34 | 0.12 | 0.46 | 2.90 | 6.30 | 18.11 |
Evolva Holding Competitive Analysis
To gauge Evolva Holding's financial strength, comparing it with Addex Therapeutics, Basilea Pharmaceutica, and Molecular Partners offers useful context. Evolva Holding is valued at 6.1 M. Evolva Holding posts a -12.78% return on equity, reflecting current earnings headwinds. Evolva Holding leads with -12.78% return on equity versus -72.84% for Addex Therapeutics. Market capitalization diverges sharply here: 694.6 M versus 6.1 M, giving Basilea Pharmaceutica a clear size advantage. Evolva Holding is dwarfed by Molecular Partners on market cap at 117.8 M versus 6.1 M.| Better Than Average | Worse Than Peers | View Performance Chart |
Evolva Holding Competition Peer Performance Charts
How to Analyze Evolva Holding Against Peers
Evolva Holding's peer analysis compares Evolva Holding with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Evolva Holding trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Evolva Holding leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Peer analysis for Evolva Holding rewards breadth of comparison over narrow single-company analysis - the more peer context incorporated, the sharper the relative assessment becomes. Comparing micro-cap peers in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care can help separate structural strengths from temporary momentum. For peer comparison, Evolva Holding has a market cap of 6.06 M.
This section for Evolva Holding SA is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules.